•
Dec 31, 2023

Ultralife Q4 2023 Earnings Report

Ultralife reported increased sales and operating income, with medical sales reaching a record high and adjusted EPS turning positive.

Key Takeaways

Ultralife Corporation reported a strong fourth quarter with a 23.4% increase in sales, driven by growth in both government/defense and commercial sectors. The company's operating income significantly improved, and adjusted EPS turned positive. Battery & Energy Products saw growth in commercial sales, particularly in medical batteries, while Communications Systems benefited from shipments to defense contractors.

Sales increased by 23.4% year-over-year, reaching $44.5 million.

Operating income rose to $3.6 million, compared to $0.2 million in the same quarter of the previous year.

Adjusted EPS was $0.18, a significant improvement from a loss of $0.03 in the fourth quarter of 2022.

Medical sales reached the highest quarterly level in the company's history.

Total Revenue
$44.5M
Previous year: $36.1M
+23.4%
EPS
$0.18
Previous year: -$0.01
-1900.0%
Gross Margin
25.6%
Operating Margin
8.2%
Adjusted EBITDA
$4.77M
Previous year: $2M
+138.6%
Gross Profit
$11.4M
Previous year: $8.1M
+40.7%
Cash and Equivalents
$10.3M
Previous year: $5.63M
+82.4%
Free Cash Flow
$1.43M
Previous year: $2.28M
-37.4%
Total Assets
$178M
Previous year: $168M
+5.8%

Ultralife

Ultralife

Ultralife Revenue by Segment

Forward Guidance

Ultralife is focused on driving additional gross margin expansion, organic growth in end markets and operating leverage. They will continue to invest in new product development for commercial expansion. Their focus in 2024 is to build upon their 2023 momentum, sustain profitable growth and generate incremental cash flow to reduce debt, and support strategic capital expenditures and accretive acquisitions.

Revenue & Expenses

Visualization of income flow from segment revenue to net income